Altogether, this preclinical work suggested that the anti-tumor immune responses induced by CTLA-4 and PD-1 blockade may represent relevant therapeutic and potentially synergistic strategies, repressing tumor progression dependent of cancer indication. The gene discussed is PDCD1; the disease is cancer.